Meta-analysis of randomized controlled trials of renal denervation in treatment-resistant hypertension

Blood Pressure

Volumn 24, Issue 5, 2015, Pages 263-274

  Fadl Elmula, Fadl Elmula M ^a,b   Jin, Yu ^c   Yang, Wen Yi ^c   Thijs, Lutgarde ^c   Lu, Yi Chao ^c   Larstorp, Anne C ^a   Persu, Alexandre ^d,e   Sapoval, Marc ^f   Rosa, Ján ^g,h   Widimský, Petr ^h   Jacobs, Lotte ^c   Renkin, Jean ^d,e   Petrák, Ondřej ^g   Chatellier, Gilles ^f,i   Shimada, Kazuyuki ^j   Widimský, Jiři ^g   Kario, Kazuomi ^j   Azizi, Michel ^f,i   Kjeldsen, Sverre E ^a,b   Staessen, Jan A ^c,k  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d Pole of Cardiovascular Research   (Belgium)

^e CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^f HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^g CHARLES UNIVERSITY   (Czech Republic)

^h CHARLES UNIVERSITY   (Czech Republic)

ⁱ INSERM   (France)

^j JICHI MEDICAL UNIVERSITY   (Japan)

^k MAASTRICHT UNIVERSITY   (Netherlands)

more..

Author keywords

Blood pressure lowering treatment; meta analysis; randomized clinical trial; renal sympathetic nervous denervation; resistant hypertension

Indexed keywords

ANTIHYPERTENSIVE AGENT; CREATININE;

AMBULATORY MONITORING; ANTIHYPERTENSIVE THERAPY; ARTICLE; ATRIAL FIBRILLATION; BLOOD PRESSURE; BODY MASS; CREATININE BLOOD LEVEL; END STAGE RENAL DISEASE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART FAILURE; HUMAN; HYPERTENSIVE CRISIS; KIDNEY DENERVATION; META ANALYSIS; OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESISTANT HYPERTENSION; RISK FACTOR; ADOLESCENT; ADULT; ADVERSE EFFECTS; AGED; DRUG EFFECTS; FEMALE; HYPERTENSION; INNERVATION; KIDNEY; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PROCEDURES; SYMPATHECTOMY; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; FEMALE; HUMANS; HYPERTENSION; KIDNEY; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SYMPATHECTOMY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84938680371     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.3109/08037051.2015.1058595     Document Type: Article

References (37)

1. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008; 117: e510-26.
2. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Press. 2013; 22: 193-278.
3. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009; 373: 1275-81.
4. Symplicity HTN-2 Investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010; 376: 1903-9.
5. Persu A, Renkin J, Thijs L, Staessen JA. Renal denervation-Ultima ratio or standard in treatment-resistant hypertension. Hypertension. 2012; 60: 596-606.
6. Bhatt DL, Kandzari DE, ONeill WW, DAgostino R, Flack JM, Katzen BT., for the SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014; 370: 1393-401.
7. Fadl Elmula FE, Hoffmann P, Larstorp AC, Fossum E, Brekke M, Kjeldsen SE, et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension. 2014; 63: 691-9.
8. Rosa J, Widimský P, Toušek P, Petrák O, Curila K, Waldauf P, et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension. 2014; 65: 407-13.
9. Azizi M, Sapoval M, Gosse P, Monge M, Bobrie G, Delsart P, et al., for the Renal Denervation for Hypertension (DENERHTN) investigators. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet. 2015; 385: 1957-65.
10. Desch S, Okon T, Heinemann D, Kulle K, Röhnert K, Sonnabend M, et al. Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension. Hypertension. 2015; 65: 1202-8.
11. Kario K, Ogawa H, Okumura K, Okura T, Saito S, Ueno T, et al. for the SYMPLICITY HTN-Japan Investigators. SYMPLICITY HTN-Japan. First randomized controlled trial of catheter-based renal denervation in Asian patients. Circ J. 2015; 79: 1222-9.
12. Moher D, Schulz KF, Altman DG., for the CONSORT Group. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet. 2001; 357: 1191-4.
13. Pokushalov E, Romanov A, Corbucci G, Artyomenko S, Baranova V, Turov A, et al. A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. J Am Coll Cardiol. 2012; 60: 1163 - 70.
14. Staessen JA, Jin Y, Thijs L, Persu A, Azizi M, Kjeldsen S. First-in-man randomized clinical trial of renal denervation for atrial arrhythmia raises concern. J Am Coll Cardiol. 2013; 62: e445-6.
15. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF., for the QUORUM Group. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUORUM statement. Lancet. 1999; 354: 1896-900.
16. Rosa J, Zelinka T, Petrák O, Štrauch B, Šomlóová Z, Indra T, et al. Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically? J Hum Hypertens. 2014; 28: 684-8.
17. Davis MI, Filion KB, Zhang D, Eisenberg MJ, Afilalo J, Schiffrin EL, Joyal D. Effectiveness of renal denervation therapy for resistant hypertension: a systematic review and meta-analysis. J Am Coll Cardiol. 2013; 62: 231-41.
18. Pancholy SB, Shantha GP, Patel TM, Sobotka PA, Kandzari DE. Meta-analysis of the effect of renal denervation on blood pressure and pulse pressure in patients with resistant systemic hypertension. Am J Cardiol. 2014; 114: 856-61.
19. Kwok CS, Loke YK, Pradhan S, Keavney B, El-Omar M, Mamas MA. Renal denervation and blood pressure reduction in resistant hypertension: a systematic review and meta-analysis. Open Heart. 2014;e 000092.
20. Colloca L, Finniss D. Nocebo effects, patient- clinician communication, and therapeutic outcomes. JAMA. 2012; 307: 567-8.
21. Jin Y, Thijs L, Persu A, Kjeldsen S, Staessen JA. No support for renal denervation in a meta-analysis. J Am Coll Cardiol. 2013; 62: 2029-30.
22. Moher D, Tsertsvadze A. Systematic reviews: when is an update an update? Lancet. 2006; 367: 881-3.
23. Korb-Savoldelli V, Gillaizeau F, Pouchot J, Lenain E, Postel-Vinay N, Plouin PF, et al. Validation of the French version of the 8-item Morisky medication adherence scale in hypertensive adults. J Clin Hypertens. 2012; 14: 429-34.
24. Kandzari DE, Bhatt DL, Brar S, Devireddy CM, Esler M, Fahy M, et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J. 2015; 36: 219-27.
25. Sakakura K, Ladich E, Cheng Q, Otsuka F, Yahagi K, Fowler DR, et al. Anatomic assessment of sympathetic peri-arterial renal nerves in man. J Am Coll Cardiol. 2014; 64: 635-43.
26. Von Euler US, Hellner S, Purkhold A. Excretion of noradrenaline in urine in hypertension. Scand J Clin Lab Invest. 1954; 6: 54-9.
27. Julius S, Esler M. Autonomic nervous cardiovascular regulation in borderline hypertension. Am J Cardiol. 1975; 36: 685-96.
28. Esler M, Zweifler A, Randall O, Julius S, DeQuattro V. Agreement among three different indices of sympathetic nervous system activity in essential hypertension. Mayo Clin Proc. 1977; 52: 379-82.
29. Esler M, Jackman G, Leonard P, Bobik A, Skews H, Jennings G, et al. Determination of noradrenaline uptake, spillover to plasma and plasma concentration in patients with essential hypertension. Clin Sci (Lond). 1980; 59 Suppl 6: 311-3s.
30. Kjeldsen SE, Flaaten B, Eide I, Helgeland A, Leren P. Increased peripheral release of noradrenaline and uptake of adrenaline in essential hypertension? Clin Sci (Lond). 1981; 61 Suppl 7: 215-7s.
31. Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension: results in 1,266 cases. JAMA. 1953; 152: 1501-4.
32. Esler M. Renal denervation for treatment of drug- resistant hypertension. Trends Cardiovasc Med. 2015; 14: 107-15.
33. Gal P, de Jong MR, Smit JJ, Adiyaman A, Staessen JA, Elvan A. Blood pressure response to renal nerve stimulation in patients undergoing renal denervation: a feasibility study. J Hum Hypertens. 2014; 29: 292-5.
34. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension. Durability of blood pressure reduction out to 24 months. Hypertension. 2011; 57: 911-7.
35. Sakakura K, Tunev S, Yahagi K, OBrien AJ, Ladich E, Kolodgie FD, et al. Comparison of histopathologic analysis following renal sympathetic denervation over multiple time points. Circ Cardiovasc Interv. 2015; 8:e001813.
36. Persu A, Jin Y, Azizi M, Baelen M, Volz S, Elvan A, et al. Blood pressure changes after renal denervation at 10 European expert centers. J Hum Hypertens. 2014; 28: 150-6.
37. Persu A, Azizi M, Jin Y, Volz S, Rosa J, Fadl Elmula FE, et al., for the European Network COordinating research on Renal Denervation (ENCOReD). consortium. Hyperresponders vs. nonresponder patients after renal denervation: do they differ? J Hypertens. 2014; 32: 2422-7.